Tepmetko (tepotinib) — United Healthcare
Non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations
Initial criteria
- Diagnosis of non-small cell lung cancer
- Disease is recurrent, advanced, or metastatic
- Tumor is MET exon 14 skipping mutation positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tepmetko therapy
Approval duration
12 months